Oscient Files Patent Suit Over Cholesterol Drug

By Jacqueline Bell (January 15, 2009, 12:00 AM EST) -- Oscient Pharmaceuticals Corp. and Ethypharm SA have launched a patent infringement lawsuit against Lupin Ltd. over the cholesterol drug Antara.

The lawsuit, filed Wednesday in the U.S. District Court for the District of Maryland, was a response to a Paragraph IV certification notice Oscient received last month notifying it that Lupin had filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking agency authorization to market a generic version of Antara.

Lupin is looking to sell generic Antara before the patent covering the drug expires in August 2020.

Oscient said Thursday its decision to initiate a suit...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!